Angiogenesis is one of the defining characteristics of cancer. Vascular endothelial growth factor (VEGF) is crucial
for the development of angiogenesis. A growing interest in cancer therapy is being caused by the widespread use
of antiangiogenic drugs in treating several types of human cancer. However, this therapeutic approach can
worsen resistance, invasion, and overall survival. As we proceed, refining combination strategies and addressing
the constraint of targeted treatments are paramount. Therefore, major challenges in using novel combinations of
antiangiogenic agents with cytotoxic treatments are currently focused on illustrating the potential of synergistic
therapeutic strategies, alongside advancements in nanomedicine and gene therapy, present opportunities for
more precise interference with angiogenesis pathways and tumor environments. Nanoparticles have the potential
to regulate several crucial activities and improve several drug limitations such as lack of selectivity, non-targeted
cytotoxicity, insufficient drug delivery at tumor sites, and multi-drug resistance based on their unique features.
The goal of this updated review is to illustrate the enormous potential of novel synergistic therapeutic strategies
and the targeted nanoparticles as an alternate strategy for t treating a variety of tumors employing anti
angiogenic therapy.